Metoclopramide Accord-Uk

Metoclopramide, the active ingredient in Metoclopramide Accord-Uk, is a dopamine antagonist (antiemetic) presented as an oral dosage form for systemic use. It is employed to relieve nausea and vomiting, improve gastric emptying in gastroparesis, and aid in the management of gastro‑oesophageal reflux disease and chemotherapy‑induced nausea.

GNH USA supplies Metoclopramide Accord-Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Metoclopramide is used to treat conditions affecting the gastrointestinal tract and nausea pathways.

Nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. Gastroparesis: accelerates gastric emptying and improves digestive symptoms. Gastro‑oesophageal reflux disease (GERD): enhances lower esophageal sphincter tone to reduce reflux. Chemotherapy‑induced nausea: prevents and controls nausea associated with anticancer treatment.

Metoclopramide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness - Fatigue - Diarrhea - Headache

Serious or Rare Side Effects: - Tardive dyskinesia (involuntary movements) - Neuroleptic malignant syndrome (fever, muscle rigidity) - Severe allergic reactions (anaphylaxis)

When prescribing Metoclopramide, clinicians should consider several safety measures.

Assess renal function: adjust use in patients with severe renal impairment. Avoid in patients with known extrapyramidal disorders: risk of worsening symptoms. Use caution in the elderly: increased susceptibility to central nervous system effects. Monitor for depression or suicidal ideation: discontinue if severe mood changes occur. Store at room temperature: keep in the original container, protect from moisture and light.

Metoclopramide can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Antipsychotics (e.g., phenothiazines, haloperidol): may reduce antiemetic efficacy and increase extrapyramidal risk. - MAO inhibitors: can potentiate central nervous system effects. - CNS depressants (e.g., opioids, benzodiazepines): increase sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome. - Opioid analgesics: may enhance gastrointestinal side effects.